Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer
Authors:
- Ayse Nuransoy CengizACAyse Nuransoy Cengiz
- Oktay BozkurtOBOktay Bozkurt
- Muhammet CengizMCMuhammet Cengiz
- Metin OzkanMOMetin Ozkan
- Mevlude InancMIMevlude Inanc
- Umut KefeliUKUmut Kefeli
- Devrim CabukDCDevrim Cabuk
- Mustafa ErmanMEMustafa Erman
- Saadettin KilickapSKSaadettin Kilickap
- Tolga KoseciTKTolga Koseci
- Duygu BayirDBDuygu Bayir
- Deniz Can GuvenDGDeniz Can Guven
Open Access
- 13 January 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 642
Abstract
Background/Objectives: Non-small-cell lung cancer (NSCLC) is a common disease with a high mortality rate and is often treated with immunotherapies; however, prognostic markers are required to identify patients who are most likely to benefit from these treatments. Therefore, we designed this study to assess the prognostic significance of the C-PLAN index, which includes performance status (PS) and C-reactive protein (CRP). Methods: A total of 560 patients were included in this multicenter study. Patients had been diagnosed with NSCLC and had received nivolumab therapy. The C-PLAN index, defined in 2022, is a score derived from the combination of PS, CRP, lactate dehydrogenase (LDH), albumin, and neutrophil–lymphocyte ratio (NLR). Patients were classified into good-, moderate-, and poor-prognosis groups according to the C-PLAN score. Results: The median metastatic overall survival was 25 months in the group with a C-PLAN score < 2 and 6 months in the group with a C-PLAN score ≥ 2 (p < 0.001). The median metastatic progression-free survival was 11 months in the group with a C-PLAN score < 2 and 3 months in the group with a C-PLAN score ≥ 2. Conclusion: This is the first comprehensive study demonstrating that the C-PLAN index can be used for prognostic purposes in immunotherapy. This score, which can be easily, economically, and practically calculated in outpatient clinics, can predict patient prognosis and determine who should receive longer durations of immunotherapy.Keywords
This publication has 34 references indexed in Scilit:
- Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCANCancer Epidemiology, 2024
- Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysisCancer Medicine, 2019
- Immunogenic cell death in anticancer chemotherapy and its impact on clinical studiesCancer Letters, 2018
- Immunogenic effects of chemotherapy-induced tumor cell deathGenes & Diseases, 2018
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic reviewCancer Letters, 2018
- Lung Cancer Staging and Prognosis2016
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Cancer-related inflammationNature, 2008
- Tumor-Induced OsteomalaciaJAMA, 2005
- What do we mean by validating a prognostic model?Statistics in Medicine, 2000